Mylan (NASDAQ:MYL) has been assigned a $41.00 target price by stock analysts at Cantor Fitzgerald in a note issued to investors on Tuesday, December 26th. The brokerage currently has a “hold” rating on the stock. Cantor Fitzgerald’s target price indicates a potential downside of 12.58% from the stock’s previous close.
Other equities analysts also recently issued reports about the stock. Wells Fargo & Co set a $32.00 target price on shares of Mylan and gave the stock a “hold” rating in a research note on Wednesday, October 4th. Royal Bank of Canada boosted their price target on shares of Mylan from $32.00 to $37.00 and gave the stock a “sector perform” rating in a research note on Tuesday, November 7th. Mizuho reissued a “buy” rating and set a $37.00 price target on shares of Mylan in a research note on Wednesday, October 4th. UBS Group reissued a “buy” rating and set a $46.00 price target on shares of Mylan in a research note on Thursday, October 5th. Finally, ValuEngine raised shares of Mylan from a “hold” rating to a “buy” rating in a research note on Friday, December 1st. Two investment analysts have rated the stock with a sell rating, seven have assigned a hold rating, twelve have assigned a buy rating and one has given a strong buy rating to the company. Mylan currently has a consensus rating of “Buy” and a consensus target price of $43.64.
Mylan (NASDAQ MYL) opened at $46.90 on Tuesday. Mylan has a 12 month low of $29.39 and a 12 month high of $47.19. The firm has a market cap of $25,060.00, a PE ratio of 28.25, a price-to-earnings-growth ratio of 1.48 and a beta of 1.38. The company has a debt-to-equity ratio of 1.05, a current ratio of 1.46 and a quick ratio of 0.95.
Mylan (NASDAQ:MYL) last announced its earnings results on Monday, November 6th. The company reported $1.10 earnings per share for the quarter, missing the Zacks’ consensus estimate of $1.20 by ($0.10). Mylan had a return on equity of 20.63% and a net margin of 7.28%. The company had revenue of $2.99 billion during the quarter, compared to the consensus estimate of $3.09 billion. During the same period in the prior year, the firm posted $1.38 earnings per share. The company’s revenue was down 2.3% on a year-over-year basis. sell-side analysts anticipate that Mylan will post 4.56 EPS for the current year.
In related news, CEO Heather M. Bresch sold 75,000 shares of the business’s stock in a transaction that occurred on Tuesday, January 9th. The shares were sold at an average price of $45.00, for a total transaction of $3,375,000.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. 0.69% of the stock is currently owned by insiders.
Several institutional investors have recently added to or reduced their stakes in the company. Hexavest Inc. boosted its holdings in shares of Mylan by 1.7% in the fourth quarter. Hexavest Inc. now owns 1,435,251 shares of the company’s stock valued at $60,725,000 after buying an additional 23,353 shares during the period. Nisa Investment Advisors LLC boosted its holdings in shares of Mylan by 170.9% in the fourth quarter. Nisa Investment Advisors LLC now owns 137,725 shares of the company’s stock valued at $5,827,000 after buying an additional 86,888 shares during the period. Greenlight Capital Inc. boosted its holdings in shares of Mylan by 0.4% in the third quarter. Greenlight Capital Inc. now owns 10,744,307 shares of the company’s stock valued at $337,048,000 after buying an additional 42,600 shares during the period. Wealthsource Partners LLC boosted its holdings in shares of Mylan by 57.6% in the third quarter. Wealthsource Partners LLC now owns 14,705 shares of the company’s stock valued at $461,000 after buying an additional 5,375 shares during the period. Finally, Americafirst Capital Management LLC acquired a new position in shares of Mylan in the third quarter valued at approximately $471,000. Institutional investors own 74.90% of the company’s stock.
WARNING: “Mylan (NASDAQ:MYL) Given a $41.00 Price Target at Cantor Fitzgerald” was originally published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this article on another website, it was illegally copied and republished in violation of US and international trademark and copyright legislation. The original version of this article can be read at https://www.dispatchtribunal.com/2018/01/14/mylan-myl-pt-set-at-41-00-by-cantor-fitzgerald.html.
Mylan Company Profile
Mylan N.V. is a global pharmaceutical company. The Company develops, licenses, manufactures, markets and distributes generic and branded generic products for resale by others; specialty pharmaceuticals, and active pharmaceutical ingredients (APIs). It operates through two segments: Generics and Specialty.
Receive News & Ratings for Mylan Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mylan and related companies with MarketBeat.com's FREE daily email newsletter.